

**APB611Hu02 50µg**  
**Active Neuraminidase (NEU)**  
**Organism Species: Homo sapiens (Human)**  
***Instruction manual***

FOR RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1st Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Ala47~Leu415

**Tags:** N-terminal His-tag

**Purity:** >98%

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

**Applications:** Cell culture; Activity Assays; In vivo assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 5.3

**Predicted Molecular Mass:** 45.0kDa

**Accurate Molecular Mass:** 46kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## [ SEQUENCE ]

AEND

```
FGLVQPLVTM EQLLWVSGRQ IGSVDTRFRIP LITATPRGTL LAFAEARKMS
SSDEGAKFIA LRRSMDQGST WSPTAFIVND GDVPDGLNLG AVVSDVETGV
VFLFYSLCAH KAGCQVASTM LVWSKDDGVS WSTPRNLSLD IGTEVFAPGP
GSGIQKQREP RKGRLIVCGH GTLERDGVFC LLSDDHGASW RYGSGVSGIP
YGQPKQENDF NPDECQPYEL PDGSVVINAR NQNNYHCHCR IVLRSYDADC
TLRPRDVTFD PELVDPVVAAGAVVTSSGIV FFSNPAHPEF RVNLTLRWSF
SNGTSWRKET VQLWPGPSGY SSLATLEGSM DGEEQAPQLY VLYEKGRNHY
TESISVAKIS VYGTL
```

## [ ACTIVITY ]

NEU (Sialidase-1) is an enzyme that catalyzes the removal of sialic acid (N-acetylneuraminic acid) moieties from glycoproteins and glycolipids. In the lysosome, this enzyme is part of a heterotrimeric complex together with beta-galactosidase and cathepsin A (CTSA). Thus a binding ELISA assay was conducted to detect the interaction of recombinant human NEU and recombinant human CTSA. Briefly, NEU were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to CTSA-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-NEU pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of NEU and CTSA was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of NEU with CTSA.

## [ IDENTIFICATION ]

TGCTGAGAACGACTTGGGTCTGTGTGCGAGCCGCTGTGTGACCATGGAGCACTGCTGTGGGTGAGCGGGGAGAGGATCGGCTGAGTGGAGCACTTCGGCATCCGGCTCATCAGAGCCACTCCGCGGGGCACTTCTCTGGCTTTGCTGAGGCAGGAAATGTCTGATCCGATGAGGGGCAAGTTGATCGCCCTGCGGAGGTCCATGG?




Figure 2. Gene Sequencing (extract)





Figure 3. SDS-PAGE

Sample: Active recombinant NEU, Human



**Figure 4. Western Blot**

**Sample: Recombinant NEU, Human;**

**Antibody: Rabbit Anti-Human NEU Ab (PAB611Hu02)**

**[ IMPORTANT NOTE ]**

The kit is designed for in vitro and research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.